|
Cancer is the only target of Onyvax. The development-stage biotech aims to come up with novel immunotherapies to treat advanced prostate and other forms of cancer. Onyvax's therapeutic cancer vaccines combine inactivated cell lines that create immune responses to tumor targets. The firm has several products in clinical trials, including lead candidate Onyvax-P, a cell vaccine that could treat hormone-resistant prostate cancer. While most of the company's candidates target specific types of cancer, its Onyvax-105 uses human monoclonal antibodies to attack the CD55 molecule, giving the therapy potential for treating many types of cancer.
|
| | | Contact Information | |
Address: |
St George's Hospital Medical School, Cranmer Terrace
London SW17 0RE, United Kingdom
| | Phone: | +44-20-8682-9494 | | Fax: | +44-20-8682-9495 |
|
| Financial
Highlights | | Fiscal Year End: | March | | Revenue (2008): | 0.60 M | | Employees (2008): | 16 |
|
|
Key People
| | • |
Chairman:
Barrie Ward
| | • |
Chief Executive:
Anthony Walker
| | • |
Head of Business Development:
Rob Johnson
|
|
|
